Analyst Price Targets — NGNE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 12, 2026 11:21 am | Mitchel Kapoor | H.C. Wainwright | $65.00 | $35.80 | StreetInsider | Neurogene (NGNE) PT Lowered to $65 at H.C. Wainwright |
| August 12, 2026 10:50 am | Debjit Chattopadhyay | Guggenheim | $81.00 | $35.80 | TheFly | Neurogene price target raised to $81 from $69 at Guggenheim |
| June 9, 2026 10:47 am | Mitchel Kapoor | H.C. Wainwright | $70.00 | $28.60 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Neurogene (NGNE) |
| June 3, 2026 11:04 am | — | UBS | $70.00 | $26.14 | TheFly | Neurogene initiated with a Buy at Rodman & Renshaw |
| April 28, 2026 10:09 am | — | Guggenheim | $69.00 | $27.05 | TheFly | Neurogene initiated with a Buy at Guggenheim |
| October 2, 2025 5:33 pm | — | H.C. Wainwright | $45.00 | $20.61 | TheFly | Neurogene looks 'deeply undervalued' after Taysha news, says H.C. Wainwright |
| April 14, 2025 11:53 am | Keith Tapper | BMO Capital | $16.00 | $10.89 | TheFly | Neurogene price target lowered to $16 from $45 at BMO Capital |
| March 25, 2025 11:01 am | Joel Beatty | Robert W. Baird | $38.00 | $14.20 | TheFly | Neurogene price target lowered to $38 from $46 at Baird |
| March 25, 2025 10:32 am | Mitchell Kapoor | H.C. Wainwright | $50.00 | $14.20 | TheFly | Neurogene price target lowered to $50 from $55 at H.C. Wainwright |
| November 20, 2024 9:53 pm | Paul Matteis | Stifel Nicolaus | $46.00 | $15.33 | StreetInsider | Neurogene (NGNE) PT Lowered to $46 at Stifel |
Latest News for NGNE
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced second quarter 2026 financial results and highlighted recent corporate updates. “The second quarter and recent months marked important progress across our NGN-401 program, highlighted by positive long-term…
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 12,555 shares of the Company's common stock to four new…
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 96,450 shares of the Company's common stock to six new…
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the pricing of its previously announced public offering of 3,500,000 shares of its common stock at a public offering price per share of $30.00 and, in lieu of common stock to certain investors, pre-funded…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NGNE.
U.S. House Trading
No House trades found for NGNE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.